ProfileGDS5678 / 1442018_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 65% 66% 77% 67% 62% 67% 70% 69% 64% 68% 68% 65% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2279369
GSM967853U87-EV human glioblastoma xenograft - Control 23.8910765
GSM967854U87-EV human glioblastoma xenograft - Control 33.9693166
GSM967855U87-EV human glioblastoma xenograft - Control 45.3178377
GSM967856U87-EV human glioblastoma xenograft - Control 54.0230767
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.770362
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1532567
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3717570
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2242469
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8588264
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1993168
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2122568
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9069365
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1023767